secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0001193125-24-211584
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences completes PEAK trial enrollment and advances past interim futility analysis
--------------------------------------------------------------------------------

- Phase 3 PEAK trial enrolled 413 GIST patients, exceeding target; top-line results expected by end of 2025.
- Independent Data Monitoring Committee recommended continuing PEAK study after pre-planned interim futility analysis.
- SUMMIT trial in NonAdvSM now expects to complete enrollment in Q1 2025, three months earlier than projected.
- Darara Dibabu appointed VP of Marketing; granted inducement award of 100,000 stock options at $10.74 per share.
- Bezuclastinib combination with sunitinib for second-line GIST is primary focus of registration-directed trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000119312524211584/0001193125-24-211584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000119312524211584/d873439d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-211584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer